Tadekinig alfa - AB2 Bio

Drug Profile

Tadekinig alfa - AB2 Bio

Alternative Names: IL-18BP - AB2 Bio; Recombinant human IL-18 binding protein - AB2 Bio

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AB2 Bio
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 1 inhibitors; Interleukin 18 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Immunological disorders
  • Phase II Adult-onset Still's disease

Most Recent Events

  • 14 Jun 2017 Adverse events and efficacy data from a phase II trial in Adult-onset Still's disease presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 15 May 2017 Phase-III clinical trials in Immunological disorders (In adolescents, In children) in USA (SC) (NCT03113760)
  • 21 Apr 2017 AB2 Bio plans a phase III trial for Immunodeficiency disorders (In children, In adolescents) (NCT03113760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top